Nadja West, a Director at Tenet Healthcare Corp (THC), sold 3,000 shares of the company on May 27, 2026, reducing her holdings to 24,805 shares. This sale is part of a trend of 17 insider sells and no insider buys at Tenet Healthcare over the past year. The stock is currently trading at $177.35, which is considered fairly valued according to GuruFocus's GF Value.

Melissa Starovasnik, a Director at Twist Bioscience Corp (TWST), sold 500 shares of the company on May 26, 2026. This transaction follows previous sales, bringing her total shares sold in the past year to 2,000, with no purchases. Twist Bioscience Corp's stock was trading at $61.04, which is significantly overvalued compared to its GF Value of $47.23, as per GuruFocus's intrinsic value estimate.

The Tennessee Valley Authority (TVA) is considering reclassifying power rates for AI data centers due to their growing demand. This initiative aims to ensure other utility consumers do not bear the increased burden of data center energy use. The TVA expects AI data centers' industrial load, currently 18%, to double by 2030, and discussions are underway with local power companies to accommodate this growth and provide flexibility in rate structures, with a proposal possibly reaching the TVA Board by August.

The Tennessee Valley Authority (TVA) announced significant cuts to executive compensation and leadership positions following pressure from President Donald Trump to reduce spending. The agency cut over $153 million in overall employee compensation, bringing the CEO's salary down from $10.5 million to an expected $500,000 next year (with performance incentives potentially reaching $1 million). Additionally, TVA eliminated 15 executive positions and consolidated several leadership roles as part of this cost-cutting initiative.

This article compares Progressive (NYSE:PGR) and Lemonade (NYSE:LMND) as financial stock investments for 2026, highlighting the trade-off between Progressive's established stability and profitability versus Lemonade's high-tech, high-growth potential driven by AI. While Progressive boasts robust financials and a conservative debt profile, Lemonade shows rapid revenue growth but is currently unprofitable, focusing on customer acquisition. The author leans towards Progressive for its predictability but suggests a small position in Lemonade for growth-oriented investors.

Derrick Dockery, a Director at Telos Corp (TLS), sold 8,000 shares of the company on May 28, 2026, reducing his total holdings to 186,591 shares. Over the past year, Dockery has sold a total of 34,600 shares with no purchases, contributing to a pattern of 18 insider sells and 0 insider buys for Telos Corp during that period. The stock is currently trading at $4.78, classified as fairly valued by its GF Value of $4.60.

This article analyzes whether Progressive or Lemonade is a better financial stock investment in 2026, contrasting Progressive's established profitability and scale with Lemonade's AI-driven, high-growth approach targeting younger demographics. It details the financial performance, risk profiles, and valuation metrics for both companies, concluding that while Lemonade offers potential high upside, Progressive provides a more predictable and stable investment. The author ultimately suggests a larger investment in Progressive.

The Metals Company (TMC) has achieved a significant regulatory milestone with the U.S. National Oceanic and Atmospheric Administration (NOAA) certifying its USA B exploration license application. This certification allows NOAA to begin preparing an Environmental Impact Statement (EIS) for proposed exploration activities in the USA B area, which covers 122,000km² of seafloor rich in polymetallic nodules. This progress follows NOAA's confirmation of compliance for TMC's USA A exploration license, advancing the company's pathway towards potential commercial development in deep-sea mining.

Merck & Co. stock rose 6% this week, driven by positive oncology pipeline updates that suggest future growth beyond its blockbuster Keytruda. Specifically, a combination therapy for lung cancer showed promising results, and another Keytruda combination received a positive opinion for bladder cancer. Analysts maintain a positive outlook, with a target price around $140, indicating potential for an 18% upside.

Stephen A. Schwarzman's Blackstone Inc. recently increased its stake in Micron Technology (MU) by 13,503 shares. TipRanks' AI Analyst, Spark, rates MU as Outperform, citing strong financial performance and a positive earnings outlook, though acknowledging risks like peak-cycle execution and overbought technical conditions. Micron Technology has seen a year-to-date price performance of 225.43% and currently has a market cap of $1010.3 billion.